VENT|03 by Ventus Therapeutics for Neuroinflammation

Ventus Therapeutics Announces Successful Completion of Phase 1 ...

In the Phase 1 trial, VENT-03 was safe and well-tolerated at doses far exceeding those planned for use in Phase 2 trials. There were no dose- ...

VENT-03, a First-in-Class cGAS Inhibitor - Ventus Therapeutics

The virtual event will feature VENT-03, a first-in-class cGAS inhibitor in development for lupus and other inflammatory disorders.

Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in ...

Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor ... WALTHAM, Mass. ... “cGAS has ...

Ventus Therapeutics Nominates Potential First-in-Class cGAS ...

In disease-relevant preclinical studies, VENT-03 demonstrated robust in vivo pharmacodynamic activity and efficacy. “cGAS is a highly coveted ...

VENT-03 by Ventus Therapeutics for Neuroinflammation: Likelihood ...

VENT-03 is under clinical development by Ventus Therapeutics and currently in Phase I for Neuroinflammation.

Ventus Therapeutics Announces First Participant Dosed in Clinical ...

Novo Nordisk has successfully dosed the first participant in a Phase 1 clinical study for NNC6022-0001 (formerly known as VENT-01) – an oral NLRP3 inhibitor ...

Ventus Therapeutics Announces Successful Completion of Phase 1 ...

VENT-03 demonstrated a favorable PK profile that supports once-daily dosing. In addition, VENT-03 reached plasma concentrations required for ...

Ventus Therapeutics: The Power of Resolution

Our two lead programs are advancing through clinical development: VENT-02, a brain-penetrant NLRP3 inhibitor, has completed Phase 1 and VENT ... inflammation, and ...

Overview - Ventus Therapeutics

... inflammation, and neurology. Overview. Others are building ... We screened our first target in 2020 and nominated three development candidates in 2022: VENT ...

Marcelo Bigal, MD, PhD: VENT-03's Modality Offers Hope for ...

Ventus Therapeutics recently initiated a phase 1 clinical trial for VENT-03, the first cGAS inhibitor to advance into clinical development.

VENT-03 by Ventus Therapeutics for Systemic Sclerosis ...

VENT-03 is under clinical development by Ventus Therapeutics and currently in Phase I for Systemic Sclerosis (Scleroderma).

Ventus Begins Phase 1 Trial for VENT-03 cGAS Inhibitor

Ventus Therapeutics is dedicated to the creation of novel small molecule medicines for complex targets in immunology, inflammation, and ...

Pipeline - Ventus Therapeutics

Pipeline ; VENT-02. Neuroinflammation, Neurodegeneration. Next-Gen Brain-Penetrant ; Next-Gen Brain-Penetrant. Wholly Owned Systemic. Inflammation, Pulmonology.

Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in ...

Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor ... WALTHAM, Mass. ... "cGAS has ...

Ventus Therapeutics Announces Results from Phase 1 Clinical Trial ...

Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor.

Ventus Therapeutics starts trials on VENT-03, a drug to inhibit cGAS ...

Ventus Therapeutics has begun trials on VENT-03, an oral drug designed to block cGAS, marking a pioneering approach in this category.

VENT-03, a First-in-Class cGAS Inhibitor - LifeSci Events

Join Ventus Therapeutics for its first virtual Program Spotlight event featuring VENT-03, a first-in-class cGAS inhibitor in development for lupus and other ...

Ventus Therapeutics Provides Updates on cGAS Inhibitor Program ...

Ventus' portfolio of cGAS inhibitors have demonstrated modulation of key endpoints in models of lupus, dermal inflammation, and chronic kidney disease.

Ventus Therapeutics Initiates Dosing in a Phase 1 Clinical Trial of ...

D. “We are bringing a highly differentiated NLRP3 inhibitor into the clinic with VENT-02, which has best-in-class potential based on its unique ...

Ventus sells its lead drug candidate to Novo Nordisk | BioPharma Dive

The experimental drug, dubbed VENT-01, is a small molecule that targets inflammasomes, which are protein complexes in immune system cells that ...